Summary

Overview
Global Capecitabine market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including bowel cancer. Capecitabine is a type of chemotherapy called an anti-metabolite. The body changes capecitabine into a common chemotherapy drug called fluorouracil. It stops cells from making and repairing DNA Open a glossary itemCancer cells need to make and repair DNA so they can grow and multiply.
Market Dynamics: Drivers & Restraints
Rise in the prevalence of cancers
Cancer is a global health challenge with a rising incidence, driven by factors like ageing populations, lifestyle changes, environmental changes, and increased screening efforts. This leads to a larger pool of patients requiring treatment, increasing the demand for cancer drugs like capecitabine. The industry gains are influenced by this trend, highlighting the need for effective cancer prevention and treatment strategies.
For instance, according to the American Cancer Society, Inc., around 1.9 million new cancer cases are expected to be diagnosed in the U.S. in 2023, and approximately 609,820 cancer-related fatalities in the U.S. in 2023, which is about 1,670 deaths per day.
Furthermore, the global capecitabine market is also driven by various other factors like, advancements in treatment options for cancers, a rise in demand for the drug and others help the market to grow during the forecast period.
Side effects associated with the drug
The global capecitabine market is hampered by various factors in that side effects associated with drugs are one of the factors which include bone marrow suppression, diarrhea, nausea, vomiting, hand-foot syndrome, fatigue, weakness, headache, dizziness, insomnia, paresthesias, abdominal pain, stomatitis, and rashes. Also, other factors like the high cost for manufacturing of capecitabine and others hinder the market during the forecast period.
Segment Analysis
The global capecitabine market is segmented based on indication, synthesis type, distribution channel and region.
The breast cancer from the indication segment accounted for approximately 42.1% of the Capecitabine market share
The breast cancer from the indication segment accounted for approximately 42.1%. In triple-negative breast cancers, adding capecitabine concurrently with standard chemotherapy has been shown to reduce the risk of recurrence but substantially increase treatment toxicity without consistent improvements in overall survival. Breast cancer segment is expected to lead highest market share owing to the factors like, rise in prescriptions of capecitabine, FDA clearance, novel product launches and others help the segment to grow during the forecast period.
For instance, in April 2023, OnQuality Pharmaceuticals a targeted oncology supportive therapy company developing innovative medications to address unmet needs in oncodermatology and oncogastroenterology and to improve the quality of life for patients receiving anticancer medications, stated that the U.S. Food and Drug Administration (FDA) has cleared our Investigational New Drug (IND) application for OQL036, a potential prophylactic treatment for capecitabine-induced hand-foot syndrome (HFS).
Moreover, Shilpa Medicare announced that it has introduced Capecitabine (Capebel) dispersible tablet (DT) with technology of faster dispersion within 90 seconds to treat colorectal and metastatic breast cancer.
Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors rising prevalence of the various types of cancer like colorectal cancer, colon cancer in the region, FDA approvals etc. Also, rising incidences of cancer can be due to several factors like physical inactivity, obesity, stress, and a sedentary lifestyle.
For instance, on December 14, 2022, the FDA approved updated labeling for capecitabine tablets (brand name Xeloda) under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date. This is the first drug to receive a labeling update under this pilot program.
Covid 19 Impact Analysis
The COVID-19 pandemic significantly impacted the economy, particularly in early 2020, with the closure of API manufacturing facilities leading to challenges such as reduced operational capacity, supply chain disruptions, and difficulties in sourcing raw materials and packaging materials. However, in the latter half of 2020, the demand for specific pharmaceuticals surged, driving increased demand for APIs used in production. This led to significant growth in the API market, highlighting the ongoing impact of the pandemic on the pharmaceutical industry.
Market Segmentation
By Indication
• Breast cancer
• Colorectal cancer
• Gastric cancer
• Pancreatic cancer
• Others
By Synthesis Type
• Chemical-based API
• Biological API
• Highly potent API (HPAPI)
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
 In February 2021, Dr. Reddy’s Laboratories Ltd. stated the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the U.S. Food and Drug Administration (USFDA).
Competitive Landscape
The major global players in the market include F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd, Shilpa Medicare limited, Atom Pharma, Global Calcium, LGM Pharma, Cipla Ltd, Teva Pharmaceuticals, Angel Biogenics Pvt Ltd, Salvavidas Pharma and among others.
Why Purchase the Report?
• To visualize the global capecitabine market segmentation based on indication , synthesis type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of capecitabine market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global capecitabine market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Indication
3.2. Snippet by Synthesis Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of cancers
4.1.1.2. Rise in demand for drug
4.1.2. Restraints
4.1.2.1. Side effects associated with the drug
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. Pipeline Analysis
5.7. Epidemiology
5.8. SWOT Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Indication
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.1.2. Market Attractiveness Index, By Indication
7.2. Breast cancer *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Colorectal cancer
7.4. Gastric cancer
7.5. Pancreatic cancer
7.6. Others
8. By Synthesis Type
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Synthesis Type
8.1.2. Market Attractiveness Index, By Synthesis Type
8.2. Chemical-based API *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Biological API
8.4. Highly potent API (HPAPI)
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Synthesis Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Synthesis Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Synthesis Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Synthesis Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Synthesis Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. F. Hoffmann-La Roche Ltd*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Sun Pharmaceutical Industries Ltd
12.3. Shilpa Medicare limited
12.4. Atom Pharma
12.5. Global Calcium
12.6. LGM Pharma
12.7. Cipla Ltd
12.8. Teva Pharmaceuticals
12.9. Angel Biogenics Pvt Ltd
12.10. Salvavidas Pharma
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us